TAIPEI (Taiwan News) — The Taiwan stock market will gain a new player as Tcm Biotech International Corp. prepares to list on the main board in April.
The company is currently traded on Taiwan’s over-the-counter market, closing at NT$237.5 (US$7.5) on Friday. It plans an underwriting price of NT$132 per share for the main board listing, according to CTEE and Anue.
Tcm Biotech is one of the few domestic drug developers with a vertically integrated model. Its business covers research and development, clinical trials, manufacturing, and distribution, according to Set News.
Chair Hsu Huan-ching (徐煥清) said the company generates nearly 90% of its revenue from pharmaceutical and medical device sales. Its product portfolio spans multiple medical specialties, including orthopedics, rehabilitation medicine, urology, and obstetrics and gynecology.
In terms of sales channels, hospitals, including medical centers and regional hospitals, account for about 90% of revenue, while clinics contribute roughly 10%, Hsu said. This structure allows the company to stay close to end-market demand while maintaining stable cash flow, supporting rapid distribution and sales growth when new products are launched.
Market analysts say that the company has long focused on disease areas with high prevalence and clear clinical demand such as liver and urinary tract conditions. This strategy helps manage development risks.
One of Tcm Biotech’s pipeline drugs, U101, is being developed to prevent recurrent urinary tract infections, particularly after treatment. Doctors commonly rely on long-term, low-dose antibiotics to prevent recurrence, a practice that can contribute to antibiotic resistance.
With few proven non-antibiotic preventive options available, U101 could address a significant unmet medical need. The market for such treatments is projected to exceed NT$316.9 billion.
Analysts say that as U101 advances toward international licensing and the company’s other products gain hospital approvals, Tcm Biotech could enter a period of stronger growth.
